Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1979;3(4):243-7.
doi: 10.1007/BF00254739.

Human pharmacokinetics of the daunorubicin-DNA complex. An alternative view of the lysosomotropic theory

R Hulhoven, G Sokal, C Harvengt

Human pharmacokinetics of the daunorubicin-DNA complex. An alternative view of the lysosomotropic theory

R Hulhoven et al. Cancer Chemother Pharmacol. 1979.

Abstract

Plasma kinetics and urinary execretion of daunorubicin (DNR) and its active metabolite, daunorubicinol (DNR-ol) were studied in 15 leukemic patients after a 4-h infusion of 75 mg DNR/m2 either as the free drug or as a complex with DNA. The data obtained after infusion of the DNR-DNA complex were compared with the data obtained after infusion of the free drug. The DNR plasma levels were found to be higher during the 2 h following the infusion of the complex; the levels of DNR-ol were only higher for a few minutes after infusion. Kinetic analysis showed that complexing with DNA does not fundamentally modify the three-compartment model described for DNR. Only quantitative modifications were observed: a marked lengthening of the alpha-phase and a shortening of the gamma-phase. Urinary excretion of DNR and DNR-ol was increased after infusion of the complexed drug, in relation to the persistence of higher plasma levels. The data recorded in this work do not confirm the lysosomotropic mechanism postulated for the DNR-DNA complex, but show a delayed distribution of DNR, which is progressively released by dissociation of the circulating DNR-DNA complex, as previously demonstrated in rabbits infused under same conditions.

PubMed Disclaimer

References

    1. Eur J Cancer. 1974 Nov;10(11):695-700 - PubMed
    1. Farmaco Sci. 1977 May;32(5):315-23 - PubMed
    1. Cancer Chemother Pharmacol. 1979;2(1):67-71 - PubMed
    1. J Pharmacol Exp Ther. 1975 Oct;195(1):41-9 - PubMed
    1. Arch Int Pharmacodyn Ther. 1977 Apr;226(2):344-5 - PubMed